Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

Asunci&oacute;n Mej&iacute;as, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children&rsquo;s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV) disease the balance between the in...

Full description

Bibliographic Details
Main Authors:	Asunci&oacute;n Mej&iacute;as, Octavio Ramilo
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-09-01
Series:	Biologics : Targets & Therapy
Online Access:	http://www.dovepress.com/review-of-palivizumab-in-the-prophylaxis-of-respiratory-syncytial-viru-a2293

Similar Items

Mechanism of human respiratory syncytial virus (hRSV) resistance to palivizumab
by: Welsh, Sarah Helen
Published: (2009)

The effect of palivizumab prophylaxis on respiratory syncytial virus-associated hospitalizations in infants with congenital diaphragmatic hernia
by: Pei-Lan Shao
Published: (2018-04-01)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
by: Ravasio Roberto, et al.
Published: (2009-02-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
by: D Wang, et al.
Published: (2008-12-01)

Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01)

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA
by: Marko Pokorn, et al.
Published: (2002-10-01)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
by: Jennifer Claydon, et al.
Published: (2017-01-01)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
by: Griffin M Pamela, et al.
Published: (2010-06-01)

Effect of SynagisⓇ (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants
by: Soo Kyoung Park, et al.
Published: (2010-03-01)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
by: M. Elhalik, et al.
Published: (2019-01-01)

Respiratory Syncytial Virus and Palivizumab: Where are We in 2014?
by: Joan Robinson
Published: (2014-01-01)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
by: M. Sanchez-Luna, et al.
Published: (2017-10-01)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
by: Abushahin A, et al.
Published: (2018-01-01)

Pathobiology of Respiratory Syncytial Virus (RSV)
by: Ralph A. Tripp, et al.
Published: (2020-07-01)

A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
by: Hsin Chi, et al.
Published: (2014-01-01)

Deriving health utility weights for infants with Respiratory Syncytial Virus (RSV)
by: Roy, Lilla MC
Published: (2013)

Deriving health utility weights for infants with Respiratory Syncytial Virus (RSV)
by: Roy, Lilla MC
Published: (2013)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01)

The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut
by: Anna Banerji, et al.
Published: (2014-01-01)

Respiratory syncytial virus (RSV) in infants hospitalized for acute lower respiratory tract disease: incidence and associated risks
by: Adriana Gut Lopes Riccetto, et al.

Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
by: Mohammed Hassan A. Mohammed, et al.
Published: (2021-02-01)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
by: Gary M. Ginsberg, et al.
Published: (2018-12-01)

Modeling household dynamics on Respiratory Syncytial Virus (RSV).
by: Wiriya Mahikul, et al.
Published: (2019-01-01)

Airway gene-expression classifiers for respiratory syncytial virus (RSV) disease severity in infants
by: Lu Wang, et al.
Published: (2021-02-01)

Defining the burden of respiratory syncytial virus infection
by: Asuncion Mejias, et al.
Published: (2013-11-01)

Respiratory Syncytial Virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice
by: Torres Juan, et al.
Published: (2010-09-01)

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
by: Turti Tatyana V, et al.
Published: (2012-09-01)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
by: Chee, Chris, et al.
Published: (2010-02-01)

Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses
by: D Wang, et al.
Published: (2011-01-01)

Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis
by: Emilie Jacque, et al.
Published: (2021-06-01)

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
by: Jafri Hasan S, et al.
Published: (2007-10-01)

The clinical burden of respiratory syncytial virus (RSV) bronchiolitis among infants in the United Kingdom (UK)
by: Murray, Joanna Catherine
Published: (2013)

Epidemiological changes of respiratory syncytial virus (RSV) infections in Israel.
by: Shira Hirsh, et al.
Published: (2014-01-01)

Perinatal Lamb Model of Respiratory Syncytial Virus (RSV) Infection
by: Mark R. Ackermann, et al.
Published: (2012-10-01)

Effects of formalin-inactivated respiratory syncytial virus (FI-RSV) in the perinatal lamb model of RSV.
by: Rachel J Derscheid, et al.
Published: (2013-01-01)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
by: Agata Antepowicz, et al.
Published: (2021-08-01)

Cannot write session to /tmp/vufind_sessions/sess_gn32e53hb7o6iium9ee11amf0p